Policy Developments - The National Healthcare Security Administration has issued a guideline for the pricing of surgical and treatment auxiliary operations, focusing on medical technology innovations such as robotic surgery and 3D printing, establishing 37 pricing items and guiding the transition from traditional to precision medicine [2] Drug and Device Approvals - Bailitianheng's drug application for iza-bren, a first-in-class EGFR×HER3 dual antibody ADC for treating recurrent or metastatic esophageal squamous cell carcinoma, has been accepted and prioritized for review by the National Medical Products Administration [4] - Heng Rui Medicine has received clinical trial approval for SHR-9839, a humanized antibody for advanced solid tumors, and HRS-4642, a KRAS G12D inhibitor [5] - Fosun Pharma's subsidiary has been approved to conduct clinical trials for HLX701 in combination with chemotherapy for advanced colorectal cancer [6] Capital Market Activities - InnoCare Pharma has entered a collaboration agreement with Shenzhen Hengtai Biotechnology for the ISM8969 project, a new NLRP3 inhibitor for CNS diseases, with a potential total payment of up to $66 million [8][9] - Zhejiang Dejin Bio completed a multi-million A round financing to advance its core product, a recombinant botulinum toxin, and for international expansion [10] Industry Developments - Ant Group's Antifor has launched a DeepSearch feature on its PC platform to assist medical professionals with literature searches and clinical diagnosis [12] - Guangzhou's political advisor has proposed a plan to develop the brain-computer interface industry, aligning with national strategies and leveraging local resources [13] Shareholder Actions - Meihua Medical announced that shareholders plan to reduce their holdings by up to 2.51% of total shares due to personal financial needs [15] - Kain Technology has voluntarily withdrawn its drug registration application for a new hepatitis B indication, which will impact its 2025 profits [16]

【重要事项】 纳指科技ETF：将于1月21日开市起至当日10:30停牌 国投白银LOF：二级市场交易价格波动较大，1月21日开市起至当日10:30停牌 凯龙高科：筹划购买金旺达控制权21日起停牌，后者主要产品包括精密行星滚柱丝杆等 【资本运作】 震裕科技：2025年第四季度来自机器人行业订单有较明显增长 百利天恒：iza-bren用于治疗复发性或转移性食管鳞癌的上市申请获受理并被纳入优先审评品种名单， 为全球首个EGFR×HER3双抗ADC上市申请获受理 上海医药：B023细胞注射液获得临床试验批准通知书 全球未有同品种同适应症的药品上市 奕帆传动：拟购买北京和利时87.07%股权，预计构成重大资产重组 康欣新材：拟3.92亿元收购宇邦半导体51%股权，实现向半导体产业的战略转型与升级 明德生物：拟共同投资设立私募基金，投向光互联、半导体等人工智能基础设施/终端产业链 中钨高新：柿竹园公司增储9.17万吨钨金属量等资源 恒瑞医药：HRS-2141片获准开展2型糖尿病适应症的临床试验 【业绩】 海康威视：2025年净利润141.88亿元，同比增长18% 建投能源：2025年净利同比预增253.38% 通富微电： ...

Industry News - The Ministry of Finance and five other departments announced the continuation of tax and fee preferential policies for community family services such as elderly care, childcare, and housekeeping, effective from January 1, 2026, to December 31, 2027. Income from these services will be exempt from VAT and calculated at 90% for taxable income [24][26] - Recently, a surge in commercial space activities has prompted banks to participate actively. Several banks, including SPDB and CMB, successfully launched satellites aimed at enhancing their risk control capabilities. Satellite remote sensing technology will allow banks to monitor loan project progress and collateral status in real-time, addressing the limitations of traditional inspections [24][26] - Starting from January 20, 2026, domestic gasoline and diesel prices will increase by 85 yuan per ton, marking the first price hike for refined oil in 2026. The average increase for 92-octane gasoline, 95-octane gasoline, and 0-octane diesel will be 0.07 yuan per liter [24][26] - Japan plans to invest over $330 billion in artificial intelligence and semiconductor sectors [25] - A recent report indicates that the shipment share of ASIC AI servers is expected to rise to 27.8% in 2026, the highest since 2023, with growth rates surpassing those of GPU AI servers [25] - Shanghai has released an action plan to enhance the linkage between futures and spot markets for non-ferrous metals, aiming to improve resource allocation and global pricing influence [25] Company News - Hikvision reported a net profit of 14.188 billion yuan for 2025, representing a year-on-year increase of 18.46% [26][34] - Hu Silicon Industry announced that its second-largest shareholder, the National Integrated Circuit Industry Investment Fund, reduced its stake by 2% between January 7 and January 19, completing the reduction plan [26] - Liou Co. announced the completion of its suspension review and will resume trading [29] - Kailong High-Tech is planning to acquire control of Jinwangda, leading to a suspension of its stock [29] - Yifan Transmission intends to purchase 87.07% of Beijing Helish's shares, which is expected to constitute a major asset restructuring [29] - Tonghu Microelectronics forecasts a net profit of 1.1 billion to 1.35 billion yuan for 2025, representing a year-on-year increase of 62.34% to 99.24% [29] - Baile Tianheng's application for the listing of iza-bren for the treatment of recurrent or metastatic esophageal squamous cell carcinoma has been accepted and included in the priority review list [29] - Guosheng Technology expects a net loss of 325 million to 650 million yuan for 2025 due to low component prices affecting revenue [29] - Kangxin New Materials plans to acquire 51% of Yubang Semiconductor for 392 million yuan, marking a strategic shift towards the semiconductor industry [29]

来源：中信建投证券 摘要：A股呈现延续震荡走势，资金重新从权重蓝筹向中小盘成长股迁移。板块上，资源、消费升级板 块强势，部分前期热门成长赛道回调，资金聚焦基本面支撑的结构性机会。财政部、发改委昨日出台多 项政策，覆盖消费、投资等领域，划定高端制造、科创长期主线。当前震荡是政策调控后的正常反应， 慢牛逻辑未变，短期板块轮动成常态，投资者应聚焦政策与业绩双优赛道。 昨日市场三大指数集体收跌，创业板指一度跌超2%。沪深两市成交额2.78万亿，较上一个交易日放量 694亿。盘面上，全市场超3100只个股下跌。从板块来看，化工板块逆势爆发，十余只成分股涨停。贵 金属概念延续强势。房地产板块表现活跃。AI应用端局部走高。下跌方面，算力硬件、商业航天等板 块跌幅居前。其中商业航天概念股集体大跌。截至收盘，沪指跌0.01%，深成指跌0.97%，创业板指 1.79%。 习近平：努力提高国民经济循环质量和效率，让内需成为经济发展的主动力。 省部级主要领导干部学习贯彻党的二十届四中全会精神专题研讨班20日上午开班。习近平指出，我国人 口多、市场大、产业全、发展动能强，有条件加快构建新发展格局。要坚持以国内大循环为主体，正确 处理消 ...

Core Viewpoint - The National Medical Products Administration (NMPA) has accepted the New Drug Application (NDA) for the innovative EGFR x HER3 dual antibody ADC drug, iza-bren, developed by BaiLi Tianheng, aimed at treating recurrent or metastatic esophageal squamous cell carcinoma (ESCC) in patients who have failed previous PD-1/PD-L1 monoclonal antibody and platinum-based chemotherapy [1][2]. Group 1: Drug Development and Approval - The NDA acceptance is based on the interim analysis results from a Phase III clinical trial, which achieved both progression-free survival (PFS) and overall survival (OS) as primary endpoints [1]. - Iza-bren has been included in the priority review list by the CDE, indicating a potential commercialization in China within the year [1]. - This drug is expected to become the first standard treatment option for esophageal cancer in the ADC category [1]. Group 2: Market Need and Patient Impact - According to GLOBOCAN 2022, there are approximately 510,000 new esophageal cancer cases globally each year, with China accounting for about 224,000 new cases, representing 43.8% of the global total [2]. - In China, over 90% of esophageal cancer cases are esophageal squamous cell carcinoma, and there is a significant unmet clinical need for effective second-line treatment options after first-line immunotherapy [2]. - Iza-bren addresses this urgent need by providing a new treatment option specifically for patients who have failed previous therapies [2]. Group 3: Clinical Research and Recognition - Iza-bren is a core product in BaiLi Tianheng's innovative pipeline, with over 40 clinical trials ongoing in China and the U.S. across more than 10 tumor types [3]. - The drug has received multiple breakthrough therapy designations from both the CDE and the FDA, highlighting its competitive advantage and broad application prospects in the global oncology treatment landscape [3].

Core Viewpoint - The National Medical Products Administration (NMPA) has accepted the New Drug Application (NDA) for iza-bren, a first-in-class EGFR x HER3 dual antibody ADC developed by BaiLi Tianheng, aimed at treating recurrent or metastatic esophageal squamous cell carcinoma (ESCC) in patients who have failed prior PD-1/PD-L1 monoclonal antibody combined with platinum-based chemotherapy [1][2]. Group 1: Drug Development and Approval - Iza-bren is the first ADC to complete critical registration studies and has been included in the priority review list by the CDE, with expectations for commercialization in China this year [1][2]. - The NDA acceptance is based on the interim analysis results from a Phase III clinical trial, which achieved dual primary endpoints of progression-free survival (PFS) and overall survival (OS) [1][2]. Group 2: Market Need and Patient Impact - Globally, there are approximately 511,000 new esophageal cancer cases and 445,000 deaths annually, with China accounting for about 224,000 new cases, representing 43.8% of the global total [2]. - In China, over 90% of esophageal cancer cases are squamous cell carcinoma, and there is a significant unmet clinical need for effective second-line treatment options after first-line immunotherapy [2]. Group 3: Clinical Research and Recognition - Iza-bren has been recognized by global regulatory agencies, with over 40 clinical trials ongoing in China and the U.S. for more than 10 types of tumors [3]. - The drug has received multiple breakthrough therapy designations, including seven from the CDE and one from the FDA, highlighting its competitive advantage and broad application prospects in cancer treatment [3].

先看海外要闻： 美股大跌，道指收跌1.76%、纳指收跌2.39%、标普500收跌2.06%；英伟达收跌4.38%，特斯拉跌4.17%，苹果跌3.46%，亚马逊跌3.40%，Meta跌 2.60%，谷歌A跌2.42%，微软跌1.16%。 马斯克兑现承诺，开源X推荐算法。 大家早上壕！ OpenAI与ServiceNow在商业软件领域达成AI Agent合作协议。 分析师：2030年前 OpenAI广告年收入有望达250亿美元。 报道：三星美国厂3月启动EUV试产，计划下半年量产特斯拉AI芯片。 花旗集团将闪迪目标股价从280美元上调至490美元。 Neuralink首例受试者：脑机接口已能实现OTA升级。 据央视，加拿大百年来首次模拟美国军事入侵；丹麦官员称欧盟已准备好对美国商品加征反制关税。 财政部长贝森特：美国计划对关键矿产设定价格下限和上限。 美国天然气期货日内涨超25%。 COMEX黄金期货涨3.70%，报4765.50美元/盎司，盘中一度刷新历史高位至4771.50美元。 国内重大事件汇总： 1、习近平:努力提高国民经济循环质量和效率，让内需成为经济发展的主动力。（新华社） 到2026年底，台积电WM ...

Group 1: Government Policies and Economic Measures - The Ministry of Finance announced multiple policies to enhance personal consumption loan interest subsidies and implement a special guarantee plan for private investment [1] - The fiscal deficit, total debt, and overall expenditure will maintain necessary levels through 2026, ensuring that overall expenditure "only increases" and key areas are "only strengthened" [1][2] - A tax and fee exemption policy for community service industries, including elderly care and childcare, will be effective from January 1, 2026, to December 31, 2027 [2] Group 2: Company News and Financial Performance - Hikvision reported a revenue of 92.518 billion yuan for 2025, with a slight year-on-year increase of 0.02%, while net profit grew by 18.46% to 14.188 billion yuan [5] - Tongfu Microelectronics expects a net profit of 1.1 billion to 1.35 billion yuan for 2025, representing a growth of 62.34% to 99.24% year-on-year [5] - Puxin Technology anticipates a net profit of 2.3 billion to 2.4 billion yuan for 2025, marking a growth of 93.18% to 101.58% year-on-year [5] - Aifan Transmission plans to acquire 87.07% of Beijing Heli Technology Co., which is expected to constitute a major asset restructuring [6][7] - Aifan Transmission's acquisition is expected to enhance its overall strength and improve business performance [7] Group 3: Clinical and Pharmaceutical Developments - Baili Tianheng received approval for its innovative drug application for a dual-target antibody ADC for treating recurrent or metastatic esophageal squamous cell carcinoma, marking a significant milestone in clinical development [8] - Aibo Medical plans to acquire at least 51% of Demai Medical, a high-tech enterprise, to expand into the sports health sector [9][10] Group 4: Market and Investment Insights - CITIC Securities reports that the recent pullback in the securities sector does not indicate the end of the market rally, suggesting potential upward paths for the sector [11]

Group 1 - The core viewpoint of the article is that Hongyuan Green Energy is forecasting a significant improvement in its financial performance for the year 2025, expecting a net profit attributable to shareholders of the parent company between 180 million and 250 million yuan, indicating a turnaround from a loss to profit compared to the previous year [2] Group 2 - The company anticipates achieving profitability in 2025, which marks a notable recovery from its previous financial performance [2] - The projected net profit range reflects a positive outlook for the company's operations and financial health moving forward [2] - The announcement is based on statutory disclosure data from the previous year, highlighting the company's commitment to transparency in its financial reporting [2]

Core Viewpoint - The company, Bai Li Tian Heng, has received formal acceptance of its New Drug Application (NDA) for its first-in-class EGFR×HER3 dual antibody ADC, Iza-bren, which is the only one to enter Phase III clinical trials globally [1][2] Group 1: Drug Development and Clinical Trials - Iza-bren has achieved dual primary endpoints of progression-free survival (PFS) and overall survival (OS) in a Phase III clinical trial for esophageal squamous cell carcinoma, as determined by an independent data monitoring committee (iDMC) [1] - The NDA acceptance is based on the interim analysis results from the Phase III clinical trial, and Iza-bren has been included in the priority review list by the National Medical Products Administration (NMPA) for the treatment of recurrent or metastatic esophageal squamous cell carcinoma [1] Group 2: Regulatory Status and Breakthrough Designations - Iza-bren is the first EGFR×HER3 dual antibody ADC to have its drug application accepted globally and is currently undergoing over 40 clinical trials for various tumor types in China and the United States [2] - As of now, Iza-bren has seven indications included in the breakthrough therapy designation list by the NMPA, two indications in the priority review list, and one indication recognized by the U.S. Food and Drug Administration (FDA) as a breakthrough therapy [2]